{"id":"W4392984296","doi":"10.1097/hep.0000000000000864","title":"Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?","year":2024,"lang":"en","type":"article","venue":"Hepatology","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Toronto General Hospital; University of Toronto; University Health Network","funders":"Genentech; Eisai; Novo Nordisk; CSL Behring; National Institute for Health and Care Research; European Association for the Study of the Liver; Pfizer; Moderna; ZonMw; Audentes Therapeutics; LifeArc; Regeneron Pharmaceuticals; Bristol-Myers Squibb; AstraZeneca; Ipsen; Alnylam Pharmaceuticals; Ultragenyx Pharmaceutical; Amsterdam University Medical Centers; EA Pharma Co., Ltd.; Gilead Sciences; American Association for the Study of Liver Diseases; Kowa Company; Sanofi; GlaxoSmithKline","keywords":"Drug; Medicine; Internal medicine; Drug approval; Pharmacology; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1115152,0.001463672,0.003781337,0.003422076,0.004073926,0.02741803,0.004849976,0.03063676,0.02092309],"category_scores_gemma":[0.2183845,0.0009830887,0.004136648,0.00389018,0.01066175,0.03174729,0.00576468,0.03195474,0.01026247],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007073786,"about_ca_system_score_gemma":0.03603159,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005098802,"about_ca_topic_score_gemma":0.008471979,"domain_scores_codex":[0.936645,0.03338327,0.007774114,0.003795932,0.01435557,0.00404609],"domain_scores_gemma":[0.7621107,0.14108,0.01652288,0.007249944,0.05767088,0.01536559],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003911059,0.0002923454,0.00124604,0.002788613,0.0002055268,0.0006548964,0.0006697644,0.0004561232,0.0004343854,0.06085104,0.5975202,0.33449],"study_design_scores_gemma":[0.0003660565,0.0002872988,0.001040688,0.009025958,0.0001704744,0.0004327017,0.0007245568,0.0004166176,0.0002578242,0.04935975,0.9377523,0.0001658808],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.0005754906,0.09393631,0.002797797,0.8716102,0.01962231,0.0001333289,0.0002964858,0.0002869826,0.01074104],"genre_scores_gemma":[0.01527372,0.1383313,0.01251116,0.7771379,0.04639535,0.0004899451,0.0006645306,0.0003778952,0.008818306],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.1115152,"threshold_uncertainty_score":0.5897559,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01797591256930351,"score_gpt":0.2776136475974494,"score_spread":0.2596377350281459,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}